Zafgen (ZFGN) Earns Daily Media Sentiment Rating of 0.03

Judith Bessette
Julho 16, 2017

The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

On Thursday, May 11th, Dennis D. Kim purchased 10,000 shares of Zafgen stock. The shares were purchased at an average cost of $4.40 per share, with a total value of $44,000.00. Zafgen has a 52-week low of $2.89 and a 52-week high of $7.09. The stock traded as high as $3.85 and last traded at $3.76, with a volume of 654,728 shares. The stock's market capitalization is $101.00 million. The company has a 50-day moving average price of $3.80 and a 200-day moving average price of $4.11.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. Equities analysts forecast that Zafgen, Inc. will post ($2.34) earnings per share for the current fiscal year. Zafgen Inc (NASDAQ:ZFGN) has declined 36.39% since July 14, 2016 and is downtrending. If you are reading this piece on another site, it was illegally stolen and reposted in violation of United States & worldwide trademark and copyright laws. The legal version of this story can be viewed at

Nobel laureate's family accuses China of guile
During the past couple of weeks, Liu Xia had been at the hospital as her husband's health deteriorated. Foreign Minister Julie Bishop says the death of Liu Xiaobo on Thursday was very sad.

A number of equities research analysts have recently commented on the company. Roth Capital began coverage on shares of Zafgen in a research note on Thursday, April 20th. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover ZFGN having a buy-equivalent rating. Zacks Investment Research upgraded Zafgen from a "hold" rating to a "buy" rating and set a $5.50 price objective for the company in a research report on Wednesday, May 10th. Finally, ValuEngine downgraded shares of Zafgen from a "sell" rating to a "strong sell" rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The stock of Zafgen Inc (NASDAQ:ZFGN) has "Neutral" rating given on Thursday, December 3 by Suntrust Robinson.

Several other brokerages have also recently weighed in on ZFGN. Dimensional Fund Advisors LP boosted its position in Zafgen by 41.5% in the fourth quarter. Paloma Partners Management Co now owns 130,000 shares of the biopharmaceutical company's stock worth $606,000 after buying an additional 19,278 shares during the period. TIAA CREF Investment Management LLC raised its position in shares of Zafgen by 40.9% in the first quarter. Renaissance Technologies LLC acquired a new position in shares of Zafgen during the first quarter worth about $840,000. Candriam Luxembourg S.C.A. now owns 213,000 shares of the biopharmaceutical company's stock valued at $993,000 after buying an additional 105,000 shares during the last quarter. Finally, Paloma Partners Management Co boosted its position in Zafgen by 17.4% in the first quarter. Federated Investors Inc. PA boosted its position in shares of Zafgen by 27.0% in the fourth quarter. Before this latest buy, Ferguson made one other purchase in the past year, buying $414,292 shares at a cost of $55.24 each.

Outros relatórios LazerEsportes

Discuta este artigo